Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Nov;1(6):696-700.
doi: 10.1128/cdli.1.6.696-700.1994.

Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes

Affiliations

Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes

M B Purner et al. Clin Diagn Lab Immunol. 1994 Nov.

Abstract

Antigen-specific cytotoxic T cells (CTL) are generally elicited in vitro by incubation of effector cells with an appropriate major histocompatibility complex-matched antigen-presenting cell (APC). In the case of CTL derived from inbred rodents, spleen cells from an animal of the same strain serve as a ready source of autologous major histocompatibility complex-identical APC. In outbred human populations, however, a convenient source of human leukocyte antigen-matched APC is ordinarily difficult to obtain, and for that reason human antigen-specific CTL may be difficult to propagate. We describe a method whereby Epstein-Barr virus-transformed human B cells (B-LCL) serve as a convenient source of efficient APC for the propagation of human antigen-specific CTL. B-LCL are produced by using B cells from the donor under study and are thus human leukocyte antigen identical to the donor. Using this method, we have propagated human CD4+ Toxoplasma gondii-specific CTL for up to 9 months in vitro, during which time the cells retained their functional capability.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1985 Mar;134(3):1676-81 - PubMed
    1. J Immunol. 1984 Jul;133(1):422-7 - PubMed
    1. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8638-42 - PubMed
    1. J Immunol. 1989 Apr 1;142(7):2482-8 - PubMed
    1. J Immunol. 1989 Sep 15;143(6):2051-7 - PubMed

Publication types

MeSH terms